icon star paper   Articles  
Back grey_arrow_rt.gif
CEL-SCI Receives Government Grant to Develop CEL-1000 Against Herpes
  VIENNA, Va., May 7 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) has been awarded a Phase I SBIR (Small Business Innovation Research) grant from the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), in the amount of $162,000 for the further development of CEL-1000 against Herpes Simplex.
This work will be done in collaboration with the lab of Dr. Kenneth S. Rosenthal of Northeastern Ohio Universities College of Medicine, Rootstown, Ohio. Dr. Rosenthal is already working with the CEL-1000 peptide and recently received a $1.1 million grant for collaborative studies with CEL-SCI for the development of CEL-1000 as a possible treatment for viral encephalitis. Viral encephalitis is a potentially lethal inflammation of the brain.
Last week, at the 16th International Conference on Antiviral Research, CEL-SCI scientists and Dr. Kenneth S. Rosenthal presented animal protection data against herpes simplex virus (HSV-1) infection. These tests utilized CEL-SCI's CEL-1000 immune-modulating peptide. The new data shows evidence of protection from disease symptoms and death after pre-treatment with CEL-1000 in a mouse skin herpes simplex virus infection model. This model closely resembles the herpes simplex virus in humans as far as disease characteristics and neuronal spread. An estimated 60 million Americans are infected with Herpes Simplex and approximately 600,000 new cases occur every year.
The researchers reported that a single dose of CEL-1000, up to four weeks prior to infection or up to three days after challenge, prevents or reduces morbidity and mortality of HSV infections. In addition, CEL-1000 was also shown to be effective without an adjuvant. Furthermore, in a separate animal study using CEL-1000 as a melanoma vaccine, CEL-1000 acted as an adjuvant itself. CEL-1000 was shown to also protect against malaria in animals in a separate study conducted at the Naval Medical Research Center.
CEL-1000 is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's immune protective immune response.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2002. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
  icon paper stack View Older Articles   Back to Top   www.natap.org